Treatment response to SGLT2 inhibitors : from clinical characteristics to genetic variations

Klen, Jasna (author), Dolžan, Vita (author)

SGLT2 (sodium-glucose cotransporter 2) inhibitors are a new class of antihyperglycaemic drugs that act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes mellitus type 2 and their cardiovascular and renal safety have been extensively investigated and confirmed in clinical trials. However, inter-individual differences in response to treatment with SGLT2 inhibitors may present in everyday clinical practice, and good predictors of glycemic response and the risk for adverse events in an individual patient are lacking. As genetic variability of SGLT2 may influence the treatment response, pharmacogenetic information could support the choice of the most beneficial treatment strategy in an individual patient. This review focuses on the clinical and genetic factors that may influence the treatment response to SGLT2 inhibitors in type 2 diabetes patients with comorbid conditions.

• Language: English
• Keywords: SGLT2 inhibitors, cardiovascular safety, renal safety, genetic polymorphisms
• Work type: Article
• Typology: 1.02 - Review Article
• Organization: MF - Faculty of Medicine
• Publication status: Published
• Publication version: Version of Record
• Publication date: 01.01.2021
• Year: 2021
• Number of pages: 12 str.
• Numbering: Vol. 22, iss. 18, art. 9800
• PID: 20.500.12556/RUL-136108
• UDC: 616.379
• ISSN on article: 1422-0067
• DOI: 10.3390/ijms22189800
• COBISS.SI-ID: 77487107
• Publication date in RUL: 13.04.2022

Record is a part of a journal

• Title: International journal of molecular sciences
• Shortened title: Int. j. mol. sci.
• Publisher: MDPI
• ISSN: 1422-0067
• COBISS.SI-ID: 2779162

Licences

• License: CC BY 4.0, Creative Commons Attribution 4.0 International
• Link: http://creativecommons.org/licenses/by/4.0/
• Description: This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
• Licensing start date: 10.09.2021

Secondary language

• Language: Slovenian
• Keywords: SGLT2 inhibitorji, kardiovaskularna varnost, nefrologija, genetski polimorfizem

Projects

• Funder: ARRS - Slovenian Research Agency
• Project number: P1-0170
• Name: Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

• Funder: ARRS - Slovenian Research Agency
• Project number: P3-0298
• Name: Geni, hormonske in osebnostne spremembe pri metabolnih motnjah